A groundbreaking study has revealed that the weight-loss jab tirzepatide may hold the key to helping individuals maintain their desired weight. This injectable medication, often referred to as the ‘King Kong’ of weight-loss jabs, has demonstrated its efficacy in helping people shed nearly 20% of their body weight.
Tirzepatide was initially recommended by the National Institute for Health and Care Excellence as a treatment option for individuals with type 2 diabetes who are unable to tolerate metformin. However, it is now being seen as a powerful weapon in the battle against obesity. Renowned US expert Dr Julio Rosenstock has even compared tirzepatide to semaglutide, another weight-loss medication, labeling the former as ‘King Kong’ in comparison to the latter’s ‘gorilla’ status.
In a recent study, researchers discovered that tirzepatide significantly aids individuals in maintaining their desired weight. The study involved 287 participants who had already achieved a weight loss of at least 5% through diet and exercise. Traditionally, individuals in this category tend to regain approximately one-third of their initial weight loss. However, when these individuals were administered tirzepatide for a year, they experienced an additional average weight loss of 18.4%.
Professor Thomas Wadden, who led the study at the University of Pennsylvania, remarked, “Slimmers often encounter a plateau where further weight loss becomes challenging, typically around the 5-10% mark. However, this drug has the potential to help individuals surpass this hurdle and achieve much more significant weight loss.” The study also revealed that tirzepatide contributed to reduced blood pressure and cholesterol levels while effectively controlling blood sugar.
The study, which was published in the esteemed journal Nature Medicine and presented at ObesityWeek 2023, involved an initial three-month weight-loss program for 806 participants. Of these individuals, 579 achieved a weight loss of at least 5% and were eligible to receive weekly tirzepatide injections. To evaluate the effectiveness of tirzepatide, the researchers compared this group with another group that received a placebo injection. The results were remarkable, as participants on tirzepatide experienced an average additional weight loss of nearly 20%, whereas the placebo group gained 2.5% of their initial weight.
Furthermore, individuals receiving tirzepatide lost an average of 15cm (6in) from their waistline. The study, which received funding from pharmaceutical giant Eli Lilly, the manufacturer of tirzepatide, also revealed that participants experienced fewer side effects of nausea, diarrhea, and constipation over time.
Critics argue that weight-loss jab users run the risk of encountering side effects and potentially becoming dependent on these injections for life. However, the promising results of this study highlight the potential of tirzepatide as a game-changing anti-obesity treatment.
Share or comment on this article: The fat jab that can help you lose a fifth of your weight – Tirzepatide is hailed as the ‘King Kong’ of anti-obesity treatment.
Denial of responsibility! Vigour Times is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
